PolyPid to Present D-PLEX₁₀₀ Microbiology Data at IDWeek
The company will detail how its surgical site treatment impacts bacterial growth and infection timelines on October 22, 2026.
Updated on Oct. 21, 2026 in Diseases — General
Live Poll
Should preventing long-term antibiotic resistance be the primary goal for evaluating new surgical infection treatments?
PolyPid is set to present findings from a pooled analysis of 2,185 patients at the IDWeek 2026 conference in Washington, D.C. on October 22, 2026. The data highlights how D-PLEX₁₀₀ influences surgical-site infection microbiology compared to standard-of-care treatments.
Why it matters
The analysis helps clinical experts understand how the treatment, which provides 30 days of controlled doxycycline release, mitigates bacterial burden. This data offers insight into surgical outcomes for infections that occur despite preventative measures.
In a pooled analysis of 134 patients with culture-positive infections, the D-PLEX₁₀₀ group saw a 60% relative risk reduction in incidence during the SHIELD II trial. The treatment also extended the median time to infection to 10.0 days, compared to 6.5 days for standard care.
The players
PolyPid
A pharmaceutical company headquartered in Petach Tikva, Israel, that focuses on developing localized treatments to prevent surgical-site infections.
FDA
The United States government agency responsible for protecting public health by regulating pharmaceutical therapies, including the granting of Breakthrough Therapy designation.
The details
The analysis compared wound microbiology across the SHIELD I, SHIELD II, and one Phase 2 trial to assess performance in patients experiencing surgical-site infections. D-PLEX₁₀₀ is designed to be administered directly into the surgical site for prolonged antibiotic release.
Timeline
October 22, 2026: Oral presentation of microbiology data at IDWeek 2026.
Health Landscape
This development aligns with the FDA Breakthrough Therapy designation, which provides a formal regulatory pathway for accelerating the development of high-impact medical treatments. The study findings contribute to the evolving clinical understanding of localized drug delivery systems in surgery.
The potential availability of D-PLEX₁₀₀ could shift post-surgical recovery standards by extending the window of protection against infections. Patients undergoing surgical procedures may eventually see improved outcomes through this localized, controlled antibiotic delivery method.
The takeaway
Advancements in localized antibiotic delivery aim to address the complex challenges of surgical-site infections that persist despite standard prophylaxis. Healthcare providers and patients can monitor ongoing regulatory updates as this technology moves through clinical validation.
What happens next
PolyPid intends to continue the regulatory review process for D-PLEX₁₀₀ with the FDA following the data presentation.
Further reading
For more information on the latest clinical research, visit the Diseases — General section.
Live Poll
Should preventing long-term antibiotic resistance be the primary goal for evaluating new surgical infection treatments?
